Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Aug 23, 2021 11:04am
491 Views
Post# 33748253

Another PDT Research Paper joins ever-growing neglected pile

Another PDT Research Paper joins ever-growing neglected pileLight-responsive and Protic Ruthenium Compounds Bearing Bathophenanthroline and Dihydroxybipyridine Ligands Achieve Nanomolar Toxicity towards Breast Cancer Cells

Photochemistry and Photobiology 2021 Aug 19. doi: 10.1111/php.13508. Online ahead of print.
 
SPECIAL ISSUE RESEARCH ARTICLE
 
Olaitan Oladipupo 1, Spenser R Brown 2, Robert W Lamb 3 4, Jessica L Gray 1, Colin G Cameron 5, Alexa R DeRegnaucourt 1, Nicholas A Ward 1, James Fletcher Hall 1, Yifei Xu 1, Courtney M Petersen 1, Fengrui Qu 1, Ambar B Shrestha 1, Matthew K Thompson 1, Marco Bonizzoni 1, Charles Edwin Webster 3, Sherri A McFarland 5, Yonghyun Kim 2, Elizabeth T Papish 1
 
Affiliations
1 Department of Chemistry and Biochemistry, The University of Alabama, Tuscaloosa, AL, 35487, USA.
2 Department of Chemical and Biological Engineering, The University of Alabama, Tuscaloosa, AL, 35487, USA.
3 Department of Chemistry, Mississippi State University, Mississippi State, MS, 39762, USA.
4 Oak Ridge Institute for Science and Education, Oak Ridge, TN, 37830, USA.
5 Department of Chemistry and Biochemistry, University of Texas, Arlington Arlington, TX, 76019, USA.
 
Abstract
 
We report new ruthenium complexes bearing the lipophilic bathophenanthroline (BPhen) ligand and dihydroxybipyridine (dhbp) ligands which differ in the placement of the OH groups ([(BPhen)2 Ru(n,n'-dhbp)]Cl2 with n = 6 and 4 in 1A and 2A , respectively). Full characterization data are reported for 1A and 2A and single crystal X-ray diffraction for 1A . Both 1A and 2A are diprotic acids. We have studied 1A , 1B , 2A , and 2B (B = deprotonated forms) by UV-vis spectroscopy and 1 photodissociates but 2 is light stable. Luminescence studies reveal that the basic forms have lower energy 3 MLCT states relative to the acidic forms. Complexes 1A and 2A produce singlet oxygen with quantum yields of 0.05 and 0.68, respectively, in acetonitrile. Complexes 1 and 2 are both photocytotoxic towards breast cancer cells, with complex 2 showing EC50 light values as low as 0.50 μM with PI values as high as >200 vs. MCF7. Computational studies were used to predict the energies of the 3 MLCT and 3 MC states. An inaccessible 3 MC state for 2B suggests a rationale for why photodissociation does not occur with the 4,4'-dhbp ligand. Low dark toxicity combined with an accessible 3 MLCT state for 1 O2 generation explains the excellent photocytotoxicity of 2.
<< Previous
Bullboard Posts
Next >>